차세대 진단 검사 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 컴포넌트별, 용도별, 최종 사용자별, 솔루션별, 모드별, 단계별(-2035년)

The global Next-Gen Diagnostic Tests Market is projected to grow from $4.5 billion in 2025 to $9.8 billion by 2035, at a compound annual growth rate (CAGR) of 7.9%. Growth is driven by advancements in personalized medicine, increased demand for early disease detection, and technological innovations in diagnostic tools, coupled with rising healthcare expenditure globally. The Next-Gen Diagnostic Tests Market is characterized by a moderately consolidated structure, with key segments including molecular diagnostics (approximately 45% market share), immunoassays (30%), and point-of-care testing (25%). These segments are driven by applications in infectious disease testing, oncology, and genetic testing. The market is witnessing a steady increase in the volume of tests conducted, particularly in molecular diagnostics, due to advancements in precision medicine and personalized healthcare.

The competitive landscape features a mix of global and regional players, with global companies such as Roche Diagnostics and Abbott Laboratories leading in innovation and market presence. There is a high degree of innovation, particularly in the development of rapid and accurate testing solutions. Mergers and acquisitions, along with strategic partnerships, are prevalent as companies aim to expand their technological capabilities and geographic reach. Recent trends indicate a focus on integrating AI and machine learning to enhance diagnostic accuracy and efficiency, further intensifying competition among market participants.

In the Next-Gen Diagnostic Tests Market, the 'Type' segment is pivotal, with molecular diagnostics leading due to their precision and ability to detect genetic markers. This segment is driven by the increasing prevalence of infectious diseases and cancer, where early detection is critical. Point-of-care testing is also gaining traction, supported by the demand for rapid and on-site diagnostic solutions. The shift towards personalized medicine is further propelling growth in this segment.

The 'Technology' segment is dominated by polymerase chain reaction (PCR) technology, which remains a cornerstone due to its high sensitivity and specificity in detecting nucleic acids. Next-generation sequencing (NGS) is rapidly advancing, driven by its comprehensive genomic analysis capabilities, which are essential for precision medicine. The integration of artificial intelligence and machine learning is enhancing diagnostic accuracy and efficiency, marking a significant trend in technological advancements.

Within the 'Application' segment, oncology diagnostics are at the forefront, fueled by the rising incidence of cancer and the need for early and accurate detection. Infectious disease diagnostics also hold a substantial share, particularly in the wake of global health crises such as COVID-19. The demand for prenatal and genetic testing is increasing, reflecting growing awareness and advancements in reproductive health technologies.

The 'End User' segment sees hospitals and diagnostic laboratories as primary consumers, given their role in providing comprehensive healthcare services. The rise of home healthcare and telemedicine is expanding the market for at-home diagnostic kits, driven by the convenience and accessibility they offer. Research institutes are also significant contributors, as they continue to explore innovative diagnostic solutions and technologies.

In the 'Component' segment, reagents and kits dominate due to their essential role in conducting diagnostic tests. The demand for advanced reagents is increasing as they enhance test accuracy and reliability. Instruments and software are also crucial, with ongoing innovations aimed at improving automation and data analysis capabilities. The integration of cloud-based solutions is a notable trend, facilitating real-time data sharing and collaboration across healthcare networks.

Geographical Overview

North America: The Next-Gen Diagnostic Tests Market in North America is mature, driven by advanced healthcare infrastructure and significant R&D investments. The United States leads the region, with strong demand from the biotechnology and pharmaceutical industries. Canada also contributes notably, focusing on personalized medicine and early disease detection.

Europe: Europe exhibits moderate market maturity, with robust demand from the healthcare and life sciences sectors. Key countries include Germany, the UK, and France, where government initiatives support innovation in diagnostic technologies, emphasizing precision medicine and early intervention.

Asia-Pacific: The Asia-Pacific region is experiencing rapid growth, driven by increasing healthcare expenditure and technological advancements. China and India are notable contributors, with expanding healthcare infrastructure and a growing focus on early diagnosis and preventive care. Japan also plays a significant role, leveraging its technological expertise.

Latin America: The market in Latin America is emerging, with Brazil and Mexico leading the demand for diagnostic tests. The region's growth is fueled by improving healthcare access and rising awareness of advanced diagnostic solutions, although challenges remain in terms of infrastructure and regulatory frameworks.

Middle East & Africa: The Middle East & Africa region is in the nascent stages of market development. The UAE and South Africa are notable countries, with investments in healthcare infrastructure and a growing emphasis on early disease detection. However, the region faces challenges related to economic disparities and limited access to advanced technologies.

Key Trends and Drivers

Trend 1 Title: Technological Advancements in Genomic Sequencing

The next-gen diagnostic tests market is significantly influenced by rapid advancements in genomic sequencing technologies. These advancements have led to more precise, faster, and cost-effective diagnostic solutions, enabling early detection and personalized treatment plans. The integration of AI and machine learning with genomic data analysis is further enhancing the accuracy of diagnostics, making it a critical component in precision medicine. This trend is driving increased adoption across healthcare providers seeking to improve patient outcomes.

Trend 2 Title: Regulatory Support and Frameworks

The establishment of supportive regulatory frameworks by health authorities globally is a key driver for the next-gen diagnostic tests market. Regulatory bodies are increasingly recognizing the importance of innovative diagnostic solutions in improving healthcare delivery. Streamlined approval processes and clear guidelines are encouraging companies to invest in R&D and bring new diagnostic technologies to market more swiftly. This regulatory support is crucial in fostering innovation and ensuring the availability of reliable diagnostic tests.

Trend 3 Title: Rise of Point-of-Care Testing

The demand for point-of-care (POC) testing is on the rise, driven by the need for rapid and accurate diagnostic results. Next-gen diagnostic tests are increasingly being designed for use at the point of care, offering convenience and efficiency in patient management. This trend is particularly prominent in remote and underserved areas where access to traditional laboratory facilities is limited. The ability to perform tests at the point of care is transforming healthcare delivery by enabling timely decision-making and reducing the burden on centralized laboratories.

Trend 4 Title: Integration of Digital Health Technologies

The integration of digital health technologies with next-gen diagnostic tests is revolutionizing the market. Wearable devices, mobile health applications, and telemedicine platforms are being used to collect and analyze health data in real-time. This integration allows for continuous monitoring and personalized healthcare solutions, enhancing patient engagement and adherence to treatment plans. The convergence of digital health and diagnostics is creating new opportunities for innovation and improving the overall efficiency of healthcare systems.

Trend 5 Title: Increasing Focus on Infectious Disease Diagnostics

The recent global health crises have underscored the importance of robust diagnostic capabilities for infectious diseases. There is a growing focus on developing next-gen diagnostic tests that can rapidly identify pathogens and provide actionable insights for disease management. This trend is driving investments in research and development to create tests that are not only fast and accurate but also scalable and adaptable to emerging infectious threats. The emphasis on infectious disease diagnostics is expected to continue as part of global efforts to strengthen healthcare resilience and preparedness.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Mode
• 2.9 Key Market Highlights by Stage
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Molecular Diagnostics
  • 4.1.2 Immunoassays
  • 4.1.3 Point-of-Care Testing
  • 4.1.4 Companion Diagnostics
  • 4.1.5 Liquid Biopsy
  • 4.1.6 Microbiome Testing
  • 4.1.7 Genetic Testing
  • 4.1.8 Proteomics
  • 4.1.9 Metabolomics
  • 4.1.10 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Instruments
  • 4.2.2 Reagents & Kits
  • 4.2.3 Software
  • 4.2.4 Consumables
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Consulting Services
  • 4.3.2 Maintenance Services
  • 4.3.3 Training Services
  • 4.3.4 Data Management Services
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Next-Generation Sequencing
  • 4.4.2 Polymerase Chain Reaction
  • 4.4.3 Mass Spectrometry
  • 4.4.4 Microarray
  • 4.4.5 Flow Cytometry
  • 4.4.6 CRISPR
  • 4.4.7 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Oncology
  • 4.5.2 Infectious Diseases
  • 4.5.3 Cardiology
  • 4.5.4 Neurology
  • 4.5.5 Prenatal Testing
  • 4.5.6 Rare Diseases
  • 4.5.7 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Diagnostic Laboratories
  • 4.6.3 Academic & Research Institutes
  • 4.6.4 Pharmaceutical & Biotechnology Companies
  • 4.6.5 Others
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Hardware
  • 4.7.2 Software
  • 4.7.3 Services
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Mode (2020-2035)
  • 4.8.1 Automated
  • 4.8.2 Semi-Automated
  • 4.8.3 Manual
  • 4.8.4 Others
• 4.9 Market Size & Forecast by Stage (2020-2035)
  • 4.9.1 Research
  • 4.9.2 Development
  • 4.9.3 Commercialization
  • 4.9.4 Others
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Integrated Solutions
  • 4.10.2 Standalone Solutions
  • 4.10.3 Custom Solutions
  • 4.10.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Component
    • 5.2.1.8 Mode
    • 5.2.1.9 Stage
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Component
    • 5.2.2.8 Mode
    • 5.2.2.9 Stage
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Component
    • 5.2.3.8 Mode
    • 5.2.3.9 Stage
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Component
    • 5.3.1.8 Mode
    • 5.3.1.9 Stage
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Component
    • 5.3.2.8 Mode
    • 5.3.2.9 Stage
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Component
    • 5.3.3.8 Mode
    • 5.3.3.9 Stage
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Component
    • 5.4.1.8 Mode
    • 5.4.1.9 Stage
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Component
    • 5.4.2.8 Mode
    • 5.4.2.9 Stage
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Component
    • 5.4.3.8 Mode
    • 5.4.3.9 Stage
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Component
    • 5.4.4.8 Mode
    • 5.4.4.9 Stage
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Component
    • 5.4.5.8 Mode
    • 5.4.5.9 Stage
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Component
    • 5.4.6.8 Mode
    • 5.4.6.9 Stage
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Component
    • 5.4.7.8 Mode
    • 5.4.7.9 Stage
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Component
    • 5.5.1.8 Mode
    • 5.5.1.9 Stage
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Component
    • 5.5.2.8 Mode
    • 5.5.2.9 Stage
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Component
    • 5.5.3.8 Mode
    • 5.5.3.9 Stage
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Component
    • 5.5.4.8 Mode
    • 5.5.4.9 Stage
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Component
    • 5.5.5.8 Mode
    • 5.5.5.9 Stage
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Component
    • 5.5.6.8 Mode
    • 5.5.6.9 Stage
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Component
    • 5.6.1.8 Mode
    • 5.6.1.9 Stage
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Component
    • 5.6.2.8 Mode
    • 5.6.2.9 Stage
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Component
    • 5.6.3.8 Mode
    • 5.6.3.9 Stage
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Component
    • 5.6.4.8 Mode
    • 5.6.4.9 Stage
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Component
    • 5.6.5.8 Mode
    • 5.6.5.9 Stage
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Roche Diagnostics
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Abbott Laboratories
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Thermo Fisher Scientific
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Siemens Healthineers
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Danaher Corporation
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Becton Dickinson and Company
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Bio-Rad Laboratories
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Hologic
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Qiagen
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Illumina
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Agilent Technologies
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 PerkinElmer
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 bioMerieux
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Sysmex Corporation
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Genomic Health
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Luminex Corporation
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Myriad Genetics
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Exact Sciences
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Cepheid
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Adaptive Biotechnologies
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us